Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Kinase Inhibitors | 9 | 2022 | 198 | 0.660 |
Why?
|
| Antineoplastic Agents | 7 | 2022 | 640 | 0.480 |
Why?
|
| Phenylurea Compounds | 4 | 2019 | 31 | 0.460 |
Why?
|
| Pyrimidines | 4 | 2019 | 145 | 0.450 |
Why?
|
| Multiple Sclerosis | 4 | 2007 | 226 | 0.430 |
Why?
|
| Giant Cell Tumor of Tendon Sheath | 2 | 2022 | 2 | 0.370 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2010 | 34 | 0.330 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2022 | 61 | 0.320 |
Why?
|
| Intubation, Intratracheal | 1 | 2010 | 194 | 0.270 |
Why?
|
| Disease Progression | 2 | 2013 | 1210 | 0.260 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2015 | 51 | 0.250 |
Why?
|
| Receptor, TIE-2 | 2 | 2017 | 7 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 875 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 217 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 140 | 0.230 |
Why?
|
| ras Proteins | 2 | 2015 | 76 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2015 | 7 | 0.220 |
Why?
|
| Anilides | 2 | 2015 | 18 | 0.220 |
Why?
|
| Aminopyridines | 2 | 2015 | 33 | 0.220 |
Why?
|
| Pyrazoles | 2 | 2017 | 88 | 0.200 |
Why?
|
| Macrophages | 2 | 2021 | 1048 | 0.200 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 1556 | 0.190 |
Why?
|
| Urea | 1 | 2022 | 41 | 0.190 |
Why?
|
| Population Surveillance | 1 | 2003 | 209 | 0.180 |
Why?
|
| Tumor Microenvironment | 3 | 2017 | 173 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 18 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 32 | 0.150 |
Why?
|
| Molecular Mimicry | 1 | 1998 | 31 | 0.140 |
Why?
|
| Myelin Sheath | 1 | 1998 | 37 | 0.140 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2015 | 17 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 20 | 0.130 |
Why?
|
| Quinolines | 1 | 2017 | 46 | 0.130 |
Why?
|
| Mice, Nude | 4 | 2021 | 286 | 0.130 |
Why?
|
| Neoplasms | 2 | 2019 | 1357 | 0.130 |
Why?
|
| Structure-Activity Relationship | 5 | 2022 | 355 | 0.130 |
Why?
|
| Pyridines | 1 | 2017 | 115 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 22 | 0.120 |
Why?
|
| Cell Proliferation | 5 | 2021 | 1029 | 0.110 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 1995 | 59 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2015 | 202 | 0.110 |
Why?
|
| Humans | 20 | 2022 | 64729 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 347 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 1007 | 0.100 |
Why?
|
| Mutation | 4 | 2019 | 2658 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 1995 | 380 | 0.100 |
Why?
|
| Immunotherapy | 1 | 1995 | 265 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 165 | 0.090 |
Why?
|
| Drug Design | 3 | 2022 | 135 | 0.090 |
Why?
|
| Amides | 2 | 2012 | 60 | 0.090 |
Why?
|
| Mice | 8 | 2021 | 11085 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 6 | 0.090 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2011 | 35 | 0.090 |
Why?
|
| Natalizumab | 1 | 2010 | 11 | 0.080 |
Why?
|
| Animals | 11 | 2021 | 21292 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2010 | 10 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 131 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2015 | 201 | 0.080 |
Why?
|
| Optical Fibers | 1 | 2010 | 11 | 0.080 |
Why?
|
| Laryngoscopes | 1 | 2010 | 22 | 0.080 |
Why?
|
| Trachea | 1 | 2010 | 83 | 0.080 |
Why?
|
| Female | 9 | 2021 | 33739 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 655 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 298 | 0.070 |
Why?
|
| Anesthesia | 1 | 2009 | 52 | 0.070 |
Why?
|
| Analgesia | 1 | 2009 | 35 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 249 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1211 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2009 | 86 | 0.070 |
Why?
|
| Male | 8 | 2021 | 30790 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2009 | 65 | 0.070 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2007 | 5 | 0.070 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2007 | 16 | 0.070 |
Why?
|
| Self Administration | 1 | 2007 | 49 | 0.070 |
Why?
|
| Injections, Intramuscular | 1 | 2007 | 71 | 0.070 |
Why?
|
| Aniline Compounds | 1 | 2007 | 40 | 0.070 |
Why?
|
| Models, Molecular | 3 | 2021 | 1157 | 0.070 |
Why?
|
| Pyridones | 1 | 2007 | 42 | 0.070 |
Why?
|
| Interferon-beta | 1 | 2007 | 79 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 623 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 235 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 164 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2015 | 7 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2007 | 365 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2015 | 960 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 870 | 0.050 |
Why?
|
| North Carolina | 1 | 2003 | 69 | 0.050 |
Why?
|
| DCC Receptor | 1 | 2022 | 2 | 0.050 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2022 | 11 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cell Movement | 2 | 2015 | 475 | 0.050 |
Why?
|
| Rats | 2 | 2021 | 1996 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2003 | 216 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 17230 | 0.040 |
Why?
|
| Middle Aged | 4 | 2021 | 18106 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2270 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2017 | 3147 | 0.040 |
Why?
|
| Epothilones | 1 | 2000 | 2 | 0.040 |
Why?
|
| Alkanes | 1 | 2000 | 16 | 0.040 |
Why?
|
| Lactones | 1 | 2000 | 16 | 0.040 |
Why?
|
| Diterpenes | 1 | 2000 | 13 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 4771 | 0.040 |
Why?
|
| Carbamates | 1 | 2000 | 26 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2000 | 102 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2019 | 49 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 43 | 0.040 |
Why?
|
| Cricetulus | 1 | 2019 | 103 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 32 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 220 | 0.040 |
Why?
|
| CHO Cells | 1 | 2019 | 191 | 0.040 |
Why?
|
| Sanitation | 1 | 1998 | 6 | 0.040 |
Why?
|
| Herpesvirus 6, Human | 1 | 1998 | 18 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1555 | 0.030 |
Why?
|
| Cell Line | 2 | 2019 | 2036 | 0.030 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 1998 | 26 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 1998 | 69 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 518 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 168 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 1998 | 131 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 526 | 0.030 |
Why?
|
| Angiopoietins | 1 | 2017 | 5 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1998 | 238 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1998 | 239 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 456 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 752 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 52 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2015 | 9 | 0.030 |
Why?
|
| Dimerization | 1 | 2015 | 145 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2015 | 42 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2015 | 60 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2015 | 114 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 81 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2015 | 78 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 129 | 0.030 |
Why?
|
| Peptides | 1 | 1998 | 588 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 213 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 208 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 461 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 317 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 235 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 200 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 710 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 702 | 0.020 |
Why?
|
| Monocytes | 1 | 2015 | 362 | 0.020 |
Why?
|
| Cell Communication | 1 | 2013 | 134 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 336 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 414 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2003 | 6803 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 70 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 5562 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2010 | 419 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 581 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 540 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 758 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2009 | 122 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2011 | 790 | 0.020 |
Why?
|
| Clinical Nursing Research | 1 | 2007 | 3 | 0.020 |
Why?
|
| Interferon beta-1b | 1 | 2007 | 5 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2009 | 62 | 0.020 |
Why?
|
| Skin Temperature | 1 | 2007 | 18 | 0.020 |
Why?
|
| Erythema | 1 | 2007 | 11 | 0.020 |
Why?
|
| Air | 1 | 2007 | 16 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2010 | 479 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 920 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2007 | 40 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2007 | 53 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 43 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 168 | 0.020 |
Why?
|
| Benzamides | 1 | 2007 | 67 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 80 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2007 | 134 | 0.020 |
Why?
|
| Nurse's Role | 1 | 2007 | 123 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1640 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 481 | 0.010 |
Why?
|
| Aged | 1 | 2019 | 14834 | 0.010 |
Why?
|
| Pyrones | 1 | 2000 | 5 | 0.010 |
Why?
|
| Alkaloids | 1 | 2000 | 8 | 0.010 |
Why?
|
| Epoxy Compounds | 1 | 2000 | 10 | 0.010 |
Why?
|
| Thiazoles | 1 | 2000 | 45 | 0.010 |
Why?
|
| Cell Count | 1 | 2000 | 129 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2000 | 143 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2000 | 140 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2753 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 426 | 0.010 |
Why?
|
| Microtubules | 1 | 2000 | 211 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 448 | 0.010 |
Why?
|
| Mitosis | 1 | 2000 | 220 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 666 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 851 | 0.010 |
Why?
|